Literature DB >> 9932655

Clinical evaluation of a peritoneal dialysis solution with 33 mmol/L bicarbonate.

G C Cancarini1, D Faict, C De Vos, R Guiberteau, A Tranaeus, L Minetti, R Maiorca.   

Abstract

OBJECTIVE: To evaluate the efficacy and safety of a new peritoneal dialysis solution with 33 mmol/L bicarbonate.
DESIGN: In an acute, prospective, randomized cross-over study, 8 patients were randomized in two groups of 4. On the first study day, the first group performed two consecutive 4-hour exchanges with a dialysis solution containing 35 mmol/L lactate: the first exchange with 13.6 g/L and the second with 38.6 g/L dextrose. On the second study day, the same type of exchanges were performed with bicarbonate. The second group underwent the same treatment, but used bicarbonate solutions on the first day and control solutions on the second study day. Thirty-three patients participated in a 2-month prospective and randomized study. After a 4-week baseline period using solutions containing 40 mmol/L lactate, the patients were dialyzed with either 33 mmol/L bicarbonate solutions or 40 mmol/L lactate solutions.
SETTING: Peritoneal dialysis units at the University Hospital of Brescia and the Niguarda Hospital of Milan, Italy.
RESULTS: Acute study: Control and bicarbonate solutions had similar effects on blood chemistries and peritoneal transport. Chronic study: Mean venous bicarbonate concentrations remained unchanged in the control group (26.6-27.2 mmol/L), but decreased significantly in the bicarbonate group from 28.8 mmol/L at the start of the study to 23.0 mmol/L after 2 months of bicarbonate administration. Other biochemical parameters remained unchanged.
CONCLUSION: A peritoneal dialysis solution with a bicarbonate level of 33 mmol/L does not adequately correct uremic acidosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9932655

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  4 in total

Review 1.  Correction of chronic metabolic acidosis for chronic kidney disease patients.

Authors:  P Roderick; N S Willis; S Blakeley; C Jones; C Tomson
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 2.  Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions.

Authors:  Mufazzal Ahmad; Hemal Shah; Theodori Pliakogiannis; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2006-09-27       Impact factor: 2.266

3.  A new peritoneal dialysis fluid for Japanese patients: a randomized non-inferiority clinical trial of safety and efficacy.

Authors:  Masaaki Nakayama; Yoshindo Kawaguchi; Takashi Akiba; Masao Kim; Hidemune Naito; Shigeko Hara; Teruhiko Maeba; Noriaki Yorioka; James A Sloand; Mark R Marshall
Journal:  Clin Exp Nephrol       Date:  2016-10-25       Impact factor: 2.801

4.  Biocompatible dialysis fluids for peritoneal dialysis.

Authors:  Htay Htay; David W Johnson; Kathryn J Wiggins; Sunil V Badve; Jonathan C Craig; Giovanni Fm Strippoli; Yeoungjee Cho
Journal:  Cochrane Database Syst Rev       Date:  2018-10-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.